top of page

About Us
Journal
Platform
Pipeline
Engage
Contact

Canurta Website Images.jpg

Canurta Journal

A collection of news, scientific papers and impact across industry, academia and events.

All Posts
Research
Events
Awards
News
Blog
Newsletter

Canurta Inc. advances public market strategy with LOI to sell assets to PharmaDrug Inc., accelerating growth, capital access and the Satoshi Trials

Canurta Inc. advances public market strategy with LOI to sell assets to PharmaDrug Inc., accelerating growth, capital access and the Satoshi Trials

Canurta Inc. advances public market strategy with LOI to sell assets to PharmaDrug Inc., accelerating growth, capital access and the Satoshi Trials

Jul 30, 2025

Canurta Signs LOI with extractX, Advances CNR-401, and Hits AI Milestone

Canurta Signs LOI with extractX, Advances CNR-401, and Hits AI Milestone

Canurta Signs LOI with extractX, Advances CNR-401, and Hits AI Milestone

Jul 3, 2025

extractX Ltd. and Canurta Therapeutics Announce Strategic Amalgamation

extractX Ltd. and Canurta Therapeutics Announce Strategic Amalgamation

extractX Ltd. and Canurta Therapeutics Announce Strategic Amalgamation

Jun 23, 2025

CNR-401 Preclinical Advancements, MedCity Pitch, and Open Innovation Initiatives

CNR-401 Preclinical Advancements, MedCity Pitch, and Open Innovation Initiatives

CNR-401 Preclinical Advancements, MedCity Pitch, and Open Innovation Initiatives

Jun 6, 2025

The Science Behind Developing Plant-Based Medications

The Science Behind Developing Plant-Based Medications

The Science Behind Developing Plant-Based Medications

May 3, 2025

Canurta Finalist at MedCity INVEST, Advances AI Therapeutics, and CEO Named Top 20 Under 40

Canurta Finalist at MedCity INVEST, Advances AI Therapeutics, and CEO Named Top 20 Under 40

Canurta Finalist at MedCity INVEST, Advances AI Therapeutics, and CEO Named Top 20 Under 40

Apr 30, 2025

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Mar 31, 2025

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Feb 28, 2025

Expanding U.S. Reach: C2MP Kickoff, JPM Healthcare Conference & SUNY Cannabis Research Highlights

Expanding U.S. Reach: C2MP Kickoff, JPM Healthcare Conference & SUNY Cannabis Research Highlights

Expanding U.S. Reach: C2MP Kickoff, JPM Healthcare Conference & SUNY Cannabis Research Highlights

Jan 30, 2025

Canurta Therapeutics at the 35th International Symposium on ALS/MND

Canurta Therapeutics at the 35th International Symposium on ALS/MND

Canurta Therapeutics at the 35th International Symposium on ALS/MND

Jan 22, 2025

ALS/MND Research, Lambton College Collaboration, and a Holiday Message from Canurta

ALS/MND Research, Lambton College Collaboration, and a Holiday Message from Canurta

ALS/MND Research, Lambton College Collaboration, and a Holiday Message from Canurta

Dec 20, 2024

Cannabinoids as Potential Therapeutics for ALS: An Overview from Preclinical and Clinical Studies

Cannabinoids as Potential Therapeutics for ALS: An Overview from Preclinical and Clinical Studies

Cannabinoids as Potential Therapeutics for ALS: An Overview from Preclinical and Clinical Studies

Dec 9, 2024

Optimization of Cannflavin Production in Germinated Seeds: Insights into Metabolomic and Antioxidant Profiles

Optimization of Cannflavin Production in Germinated Seeds: Insights into Metabolomic and Antioxidant Profiles

Optimization of Cannflavin Production in Germinated Seeds: Insights into Metabolomic and Antioxidant Profiles

Dec 2, 2024

November Momentum: Presenting at ALS/MND Symposium, Joining NVIDIA Inception, and Advancing R&D

November Momentum: Presenting at ALS/MND Symposium, Joining NVIDIA Inception, and Advancing R&D

November Momentum: Presenting at ALS/MND Symposium, Joining NVIDIA Inception, and Advancing R&D

Nov 29, 2024

Medical Marijuana for ALS Symptom Management: Potential Benefits and Risks in Disease Progression

Medical Marijuana for ALS Symptom Management: Potential Benefits and Risks in Disease Progression

Medical Marijuana for ALS Symptom Management: Potential Benefits and Risks in Disease Progression

Nov 25, 2024

CEO Message: New Funding, Industry Recognition, Research Breakthroughs & October Milestones

CEO Message: New Funding, Industry Recognition, Research Breakthroughs & October Milestones

CEO Message: New Funding, Industry Recognition, Research Breakthroughs & October Milestones

Oct 31, 2024

Cannabistilbene I as a Potential Therapeutic for Cardiac Hypertrophy: Modulating Key Enzymes and Metabolic Pathways

Cannabistilbene I as a Potential Therapeutic for Cardiac Hypertrophy: Modulating Key Enzymes and Metabolic Pathways

Cannabistilbene I as a Potential Therapeutic for Cardiac Hypertrophy: Modulating Key Enzymes and Metabolic Pathways

Oct 11, 2024

3-Minute Pitch at ACT Canada Consortium: Advancing ALS Treatment with CNR-401

3-Minute Pitch at ACT Canada Consortium: Advancing ALS Treatment with CNR-401

3-Minute Pitch at ACT Canada Consortium: Advancing ALS Treatment with CNR-401

Oct 10, 2024

CEO Letter: Financing Tailwinds, US Showcase for Canurta Naturals, and New R&D Progress

CEO Letter: Financing Tailwinds, US Showcase for Canurta Naturals, and New R&D Progress

CEO Letter: Financing Tailwinds, US Showcase for Canurta Naturals, and New R&D Progress

Oct 1, 2024

Letter from the CEO, CannMedTM 2024 Highlights, and More

Letter from the CEO, CannMedTM 2024 Highlights, and More

Letter from the CEO, CannMedTM 2024 Highlights, and More

Aug 30, 2024

Transforming Rare Polyphenols into Botanical Drugs

Stay connected & receive updates on new discoveries, product innovation and more.

Yes, I consent to receiving emails from Canurta Therapeutics about news, updates, and relevant content. I understand I can unsubscribe at any time.

Thank you for subscribing.

© 2025 Canurta, Inc. All rights reserved.

bottom of page